Alzheimer’s disease (AD) is caused by synaptic failure and the excessive accumulation of misfolded proteins especially Aβ and tau, and associated with memory loss and cognitive impairment. Treatment of AD mainly con...Alzheimer’s disease (AD) is caused by synaptic failure and the excessive accumulation of misfolded proteins especially Aβ and tau, and associated with memory loss and cognitive impairment. Treatment of AD mainly consists of symptomatic therapy and disease-modifying therapy (DMT). Several monotherapies including small molecules or antibodies have been evaluated through multiple clinical trials, but a very few have been approved by the USFDA to intervene the disease’s pathogenesis. Past research has shown multifactorial nature of AD, therefore, multi-target drugs were proposed to target different pathways at the same time, however, currently no rationally designed multi-target directed ligand (MTDL) has been clinically approved. Different combinations and bispecific antibodies are also under development. Novel approaches like stem cell-based therapies, microRNAs, peptides, ADCs and vaccines cast a new hope for AD treatment, however, a number of questions remained to be answered prior to their safe and effective clinical translation. This review explores the small molecules, MTDL, and antibodies (monospecific and bispecific) for the treatment of AD. Finally, future perspectives (stem cell therapy, PROTAC approaches, microRNAs, ADC, peptides and vaccines) are also discussed with regard to their clinical applications and feasibility.展开更多
目的探讨银杏叶提取物对帕金森患者血清黑质二价金属离子转运蛋白(divalent metal transporter1,DMT1)、葡萄糖调节蛋白75(glucose regulated protein 75,grp75)及神经功能的影响。方法帕金森患者38例,根据用药不同分为对照组和实验组,...目的探讨银杏叶提取物对帕金森患者血清黑质二价金属离子转运蛋白(divalent metal transporter1,DMT1)、葡萄糖调节蛋白75(glucose regulated protein 75,grp75)及神经功能的影响。方法帕金森患者38例,根据用药不同分为对照组和实验组,每组各19例,对照组患者给予多巴丝肼片,实验组在对照组的基础上给予银杏叶提取物片,治疗连续4周。治疗结束后,对所有患者黑质DMT1、grp75及认知功能进行检测。结果与治疗前相比,治疗后2组患者的黑质DMT1水平较低(P<0.05);与对照组相比,实验组患者治疗后黑质DMT1水平较低(P<0.05)。与治疗前相比,治疗后2组患者的grp75水平较高(P<0.05),与对照组相比,实验组患者治疗后grp75水平较高(P<0.05)。与治疗前相比,治疗后2组患者的Mo CA评分较高(P<0.05),HAMD评分较低(P<0.05);与对照组相比,实验组患者治疗后Mo CA评分较高(P<0.05),HAMD评分较低(P<0.05)。结论银杏叶提取物能够显著降低帕金森患者黑质DMT1水平,升高grp75水平,改善认知功能。展开更多
文摘Alzheimer’s disease (AD) is caused by synaptic failure and the excessive accumulation of misfolded proteins especially Aβ and tau, and associated with memory loss and cognitive impairment. Treatment of AD mainly consists of symptomatic therapy and disease-modifying therapy (DMT). Several monotherapies including small molecules or antibodies have been evaluated through multiple clinical trials, but a very few have been approved by the USFDA to intervene the disease’s pathogenesis. Past research has shown multifactorial nature of AD, therefore, multi-target drugs were proposed to target different pathways at the same time, however, currently no rationally designed multi-target directed ligand (MTDL) has been clinically approved. Different combinations and bispecific antibodies are also under development. Novel approaches like stem cell-based therapies, microRNAs, peptides, ADCs and vaccines cast a new hope for AD treatment, however, a number of questions remained to be answered prior to their safe and effective clinical translation. This review explores the small molecules, MTDL, and antibodies (monospecific and bispecific) for the treatment of AD. Finally, future perspectives (stem cell therapy, PROTAC approaches, microRNAs, ADC, peptides and vaccines) are also discussed with regard to their clinical applications and feasibility.
文摘目的探讨银杏叶提取物对帕金森患者血清黑质二价金属离子转运蛋白(divalent metal transporter1,DMT1)、葡萄糖调节蛋白75(glucose regulated protein 75,grp75)及神经功能的影响。方法帕金森患者38例,根据用药不同分为对照组和实验组,每组各19例,对照组患者给予多巴丝肼片,实验组在对照组的基础上给予银杏叶提取物片,治疗连续4周。治疗结束后,对所有患者黑质DMT1、grp75及认知功能进行检测。结果与治疗前相比,治疗后2组患者的黑质DMT1水平较低(P<0.05);与对照组相比,实验组患者治疗后黑质DMT1水平较低(P<0.05)。与治疗前相比,治疗后2组患者的grp75水平较高(P<0.05),与对照组相比,实验组患者治疗后grp75水平较高(P<0.05)。与治疗前相比,治疗后2组患者的Mo CA评分较高(P<0.05),HAMD评分较低(P<0.05);与对照组相比,实验组患者治疗后Mo CA评分较高(P<0.05),HAMD评分较低(P<0.05)。结论银杏叶提取物能够显著降低帕金森患者黑质DMT1水平,升高grp75水平,改善认知功能。
